Vijaya Bharti

This paper shows CDK4/6 inhibitors make breast cancer cells more susceptible to NK cell therapy by increasing surface proteins that NK cells recognize.

This study evaluates how CDK4/6 and AURKA inhibition enhances NK cell homing and tumor-killing in melanoma models using tumor-on-a-chip platforms.

This study shows that macromolecular diABZI conjugates activate STING in vitro and in vivo, with similar potency to small molecule agonists, suggesting new strategies for STING agonist delivery.